


U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		DATE: September 30, 2005
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application No. (if known): 10/551456
INTERNATIONAL APPLICATION NO.: PCT/IN2004/000092	INTERNATIONAL FILING DATE: April 5, 2004	PRIORITY DATE CLAIMED: April 3, 2003
TITLE OF INVENTION: PROGRAMMED DRUG DELIVERY SYSTEM		
APPLICANT(S) FOR DO/EO/US: Nitin B. DHARMADHIKARI et al.		
Applicant hereby submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 USC 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)): a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
ITEMS 11. TO 20. BELOW CONCERN OTHER DOCUMENT(S) OR INFORMATION INCLUDED:		
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98 together with PTO/SB/08, international search report, and 6 refs.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. ASSIGNEE NAME AND ADDRESS: SUN PHARMACEUTICAL INDUSTRIES LIMITED, Mumbai, India Please publish the assignee data with the application.</p> <p>13. <input type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 C.F.R. 1.76</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>		

U.S. APPLICATION NO. (if known) 107551456	INTERNATIONAL APPLICATION NO. PCT/IN2004/000092	DATE: September 30, 2005	
The following fees are submitted:		CALCULATIONS	PTO USE ONLY
21. <input checked="" type="checkbox"/> Basic National Stage Fee \$300		\$300.00	
22. <input checked="" type="checkbox"/> National Stage Examination Fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) All other situations \$100 \$200		\$200.00	
23. <input checked="" type="checkbox"/> National Stage Search Fee Search fee (37 CFR 1.445(a)(2) has been paid on the international application to the USPTO as an International Searching Authority International Search Report prepared and provided to the Office \$400 All other situations \$500		\$400.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$900.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
TOTAL	18-20 =		X \$ 50.00
INDEPENDENT	1-3 =		X \$ 200.00
Multiple dependent claim(s) (if applicable)		+ \$360.00	
TOTAL OF ABOVE CALCULATIONS =		\$900.00	
National Stage Application Size Fee-for each additional 50 sheets that exceeds 100 sheets \$ 250.00.			
Reduction by 1/2 for filing by small entity, if applicable. (Note 37 CFR 1.9, 1.27, 1.28).			
SUBTOTAL =		\$900.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +			
TOTAL NATIONAL FEE =		\$900.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$40.00	
TOTAL FEES ENCLOSED =		\$940.00	
		Amount to be: refunded charged	\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$940.00 to cover the above fees is enclosed. (\$300.00 for basic national stage fee; \$400.00 for national stage search fee; \$200.00 for national stage examination fee and \$40.00 for assignment recordation fee).</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. 50-2866 in the amount of \$____ to cover the above fees.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2866.</p>			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed to request that the application be restored to pending status.			
Send All Correspondence To:		WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP 1250 Connecticut Avenue NW Suite 700 Washington, DC 20036 CUSTOMER NO. 38834	
Typed or Printed Name: Nicolas E. Seckel		Reg. No.: 44,373	
Signature 		Date: September 30, 2005	